Thursday, June 22, 2017
 
 
Company News: Page (1) of 1 - 03/14/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
LYNPARZA (olaparib) Phase III SOLO-2 Data Demonstrated Progression-Free Survival Benefit in BRCA-Mutated Ovarian Cancer as Maintenance Therapy

(March 14, 2017)
Our Apologies, This article is no longer available, You may have followed an outdated link.


Page: 1


Related Keywords:
Related Sites: HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines